Research Topics
Genomes and Genes | Richard DodelSummaryAffiliation: Philipps University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's diseaseJudith Dams
Department of Neurology, Philipps University, Marburg, Germany
Health Qual Life Outcomes 11:35. 2013..We aimed to develop an estimation algorithm for EuroQol- 5 dimensions (EQ-5D)-based utilities from the clinical UPDRS or disease-specific HrQoL data in the absence of original utilities estimates...
Mechanisms of action of naturally occurring antibodies against β-amyloid on microgliaMaike Gold
Department of Neurology, Philipps University of Marburg, Baldingerstraße 1, 35043, Marburg, Germany
J Neuroinflammation 10:5. 2013....
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel
University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany
Lancet Neurol 12:233-43. 2013..We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients...
Health-related quality of life in patients with narcolepsyRichard Dodel
Department of Neurology, Philipps University, Marburg, Germany
Sleep Med 8:733-41. 2007..To evaluate the health-related quality of life (HRQoL) in patients suffering from narcolepsy...
Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's diseaseRichard Dodel
Department of Neurology, Philipps University Marburg, D 35043 Marburg, Germany
J Neurosci 31:5847-54. 2011..These findings suggest a novel physiological mechanism involving NAbs-Aβ to dispose of proteins or peptides that are prone to forming toxic aggregates...
Cost of illness in subarachnoid hemorrhage: a German longitudinal studyRichard Dodel
Department of Neurology, Philipps University Marburg, Marburg, Germany
Stroke 41:2918-23. 2010..The objective was to evaluate first-year costs in German patients with aneurysmal SAH and to identify independent determinants of costs...
Lewy body dementia and Parkinson's disease with dementiaRichard Dodel
Dept of Neurology, Philipps University Marburg, Marburg, Germany
J Neurol 255:39-47. 2008..This article focuses on the clinical issues related to both disorders and is based on a meeting of experts which took place in April 2008 in Dresden...
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidenceRichard Dodel
Department of Neurology, Philipps University, Marburg, Germany
Drugs 70:513-28. 2010..In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders...
[Innovative treatment approaches for Alzheimer's disease. Immunotherapy]R Dodel
Arbeitsgruppe Neurologische Therapieforschung, Neurologische Klinik, Philipps Universitat Marburg, Rudolf Bultmann Strasse 8, 35039, Marburg
Nervenarzt 79:149-57; quiz 158. 2008..In this review we present the current status of the different approaches in relation to Alzheimer's disease as well as to other neurodegenerative disorders...
[The costs of epilepsy in Germany]Richard Dodel
Neurologische Klinik, , Rudolf-Bultmannstr. 8, 35039 Marburg
Pharm Unserer Zeit 36:298-305. 2007
Health economic burden of patients with restless legs syndrome in a German ambulatory settingRichard Dodel
Department of Neurology, Philipps University Marburg, Marburg, Germany
Pharmacoeconomics 28:381-93. 2010..RLS places a notable financial burden on society as well as on patients and their families. More detailed studies are needed to evaluate the health economic impact of this disorder...
Trends in resource utilization for Parkinson's disease in GermanyYaroslav Winter
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Str 8, 35039 Marburg, Germany
J Neurol Sci 294:18-22. 2010..The prevalence of Parkinson's disease (PD) and costs of healthcare resources for this disease have been increasing in recent years. The objective was to determine the trends in the resource utilization for PD in Germany...
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort studyYaroslav Winter
Department of Neurology, Philipps University Marburg, Rudolf Bultmannstr 8, 35039, Marburg, Germany
J Neurol 257:638-45. 2010..The analysis of determinants of HrQoL showed that a greater attention should be paid to social support and home care. Our data on HrQoL in PD should be considered in the development of new health care programs...
The role of macrophage migration inhibitory factor in Alzheimer's diseaseMichael Bacher
Department of Neurology, Philipps University Marburg, Germany
Mol Med 16:116-21. 2010....
Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's diseaseJan Philipp Bach
Philipps University Marburg, Department of Neurology, Germany
J Neurol Sci 314:41-7. 2012..Likewise, the reported impact of drug costs on total direct costs varies across different studies. In addition, the influence of comorbidities on both treatment costs and health-related quality of life has not been adequately evaluated...
Health-related quality of life in multiple system atrophy and progressive supranuclear palsyYaroslav Winter
Department of Neurology, Philipps University Marburg, Marburg, Germany
Neurodegener Dis 8:438-46. 2011..The objective of our cross-sectional study was to evaluate the HrQoL in patients with APS and to identify the determinants of HrQoL...
Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort studyYaroslav Winter
Department of Neurology, Philipps University Marburg, Marburg, Germany
Neurodegener Dis 7:365-72. 2010..The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian cohort of patients and identify cost-driving factors of drug therapy...
Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in GermanyHajo M Hamer
Department of Neurology, Philipps University, Marburg, Germany
Epilepsia 47:2165-72. 2006..There are only few studies on the costs of epilepsy in Germany. Therefore, we performed a pilot study to estimate the direct and indirect costs of refractory epilepsy in a German epilepsy center...
Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cellsNina Baron
Department of Neurology, Philipps University Marburg, Marburg, Germany
J Neurosci Res 89:711-7. 2011..These results underscore the importance of MIF in GBM and show that MIF and its receptors may be a promising target for the treatment of malignant gliomas...
The socioeconomic impact of narcolepsyRichard Dodel
Department of Neurology, Friedrich Wilhelms University Bonn, Germany
Sleep 27:1123-8. 2004..To evaluate the economic burden of patients suffering from narcolepsy...
Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophyYaroslav Winter
Department of Neurology, Philipps University Marburg, Rudolf Bultmannstr 8, Marburg, Germany
J Neurol 257:1473-81. 2010..In addition to the treatment of motor symptoms, greater attention should be paid to the treatment of depression, which was found to be among the independent predictors of the HRQoL in ALS and MG...
Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort studyYaroslav Winter
Dept of Neurology, Philipps University Marburg, Rudolf Bultmannstr 8, 35039 Marburg, Germany
Parkinsonism Relat Disord 16:243-8. 2010..Our data should be considered in the development of national healthcare programs that seek to provide better social services support for patients with PD...
Costs of illness and care in Parkinson's disease: an evaluation in six countriesSonja von Campenhausen
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Strasse 8, Marburg, Germany
Eur Neuropsychopharmacol 21:180-91. 2011..However, inpatient care, long-term care and medication were identified as the major expenditures in the investigated countries...
Costs of Parkinson's disease in eastern Europe: a Czech cohort studyYaroslav Winter
Dept of Neurology, Philipps University, Marburg, Germany
Parkinsonism Relat Disord 16:51-6. 2010..More intensive government support for patients with chronic diseases such as PD and the development of disease-management programs that incorporate both the clinical and economic effects of PD treatment are needed...
Evaluation of health-care utilization among adult patients with epilepsy in GermanyAdam Strzelczyk
Department of Neurology and Epilepsy Center Hessen, Philipps University, Marburg, Germany
Epilepsy Behav 23:451-7. 2012..9%) and days off due to seizures (26.2%). The mean costs of epilepsy found in our study were lower than those found in studies conducted at European epilepsy centers due to the inclusion of patients in all health-care sectors...
APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasksStephan Röskam
Department of Neurology, Research Group for Neurological Therapeutics, Biomedical Research Centre, Philipps University Marburg, Hans Meerwein Strasse, 35043 Marburg, Germany
Neurosci Biobehav Rev 34:487-99. 2010..This review focuses on such cognitive outcomes of different active and passive immunization strategies in APP transgenic mice...
Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's diseaseMichael Bacher
Department of Neurology, Philipps University, Rudolf Bultmann Str 8, 35033 Marburg, Germany
Neurosci Lett 449:240-5. 2009..Further studies with human immunoglobulins and particularly with those that recognize different Abeta-epitopes are required in order to delineate in more detail the mode of action of NAbs-Abeta...
Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort studyYaroslav Winter
Department of Neurology, Philipps University Marburg, Rudolf Bultmannstrasse 8, Marburg, Germany
Parkinsonism Relat Disord 17:265-9. 2011..In particular, these programmes should concentrate not only on motor but also on non-motor manifestations of PD...
Costs of illness in a Russian cohort of patients with Parkinson's diseaseYaroslav Winter
Department of Neurology, Philipps University Marburg, Marburg, Germany
Pharmacoeconomics 27:571-84. 2009..While cost-of-illness studies for PD from developed countries have recently been published, data for Eastern Europe and Asia are still lacking...
The role of CNI-1493 in the function of primary microglia with respect to amyloid-βJan Philipp Bach
Department of Neurology, Philipps University Marburg, Marburg, Germany
J Alzheimers Dis 26:69-80. 2011..Therefore, CNI-1493 is a promising candidate for the treatment of AD...
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson diseaseDaniela Besong-Agbo
Department of Neurology, Philipps University Marburg, Marburg
Neurology 80:169-75. 2013..Recently, naturally occurring autoantibodies against α-Syn (α-Syn-nAbs) have been detected in the serum of patients with PD. They represent a putative diagnostic marker for PD...
Cost-of-illness in multiple system atrophy and progressive supranuclear palsyYaroslav Winter
Department of Neurology, Philipps University Marburg, Baldingerstrasse, 35043, Marburg, Germany
J Neurol 258:1827-34. 2011..The early diagnosis and treatment of depression in patients with atypical parkinsonian syndromes as well as programs aimed to improve social support will reduce disease-related costs...
Parkinson's disease and dementia: a longitudinal study (DEMPARK)Monika Balzer-Geldsetzer
Department of Neurology, Philipps University Marburg, Marburg, Germany
Neuroepidemiology 37:168-76. 2011..Parkinson's disease (PD) is a progressive neurodegenerative motor disorder. However, non-motor complications frequently alter the course of the disease. A particularly disabling non-motor symptom is dementia...
[Cost of illness and health service patterns in Morbus Parkinson in Austria]Sonja von Campenhausen
Neurologische Klinik, Philipps Universitat Marburg, Germany
Wien Klin Wochenschr 121:574-82. 2009..Continuously increasing healthcare costs and the fact that the prevalence of PD is expected to double in the next 25 years highlight the importance of health-economic evaluation in PD...
Affective and cognitive Theory of Mind in patients with parkinson's diseaseMaren E Bodden
Department of Neurology, Philipps University Marburg, Marburg, Germany
Parkinsonism Relat Disord 16:466-70. 2010....
Cost of illness in patients with Gilles de la Tourette's syndromeInes Dodel
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Str 8, Marburg, Germany
J Neurol 257:1055-61. 2010..Unfortunately, no cost of illness studies are available for comparison. Further health economic studies, especially cost-effectiveness studies, are necessary for a basis for rational resource allocation...
Immunotherapy and naturally occurring autoantibodies in neurodegenerative disordersFrauke Neff
Department of Neurology, Philipps University Marburg, Germany
Autoimmun Rev 7:501-7. 2008..In this review the current knowledge on the role of naturally occurring autoantibodies is discussed in respect to neurodegenerative disorders...
Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in GermanyAdam Strzelczyk
Department of Neurology and Epilepsy Center Hessen, Philipps University, Marburg, Germany Electronic address
Epilepsy Behav 27:433-8. 2013..The amount and distribution of indirect cost components remained unchanged...
Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological reviewJudith Dams
Department of Neurology, Philipps University, Marburg, Germany
Pharmacoeconomics 29:1025-49. 2011..Adverse events of treatment, co-morbidities or disease complications are not yet sufficiently included in the models to adequately represent clinical reality...
The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumorsJan Philipp Bach
Department of Neurology, Philipps University Marburg, Marburg, Germany
Cancer 115:2031-40. 2009..quot; The aim of this article was thus to present a detailed review of current knowledge regarding the role of MIF in CNS tumor pathophysiology...
Pharmacoeconomic considerations of treating patients with advanced Parkinson's diseaseJens P Reese
Philipps University Marburg, Department of Neurology, Baldingerstrasse, 35043 Marburg, Germany
Expert Opin Pharmacother 13:939-58. 2012..To date, no economic evaluation has been undertaken for possible neuroprotective/disease modifying effects, and further research is needed for evaluations of interventions for non-motor symptoms...
Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdownJorg Schrader
Department of Neurology, University of Marburg, Marburg, Germany
BMC Cancer 9:464. 2009..Studies of the role of the cytokine macrophage-migration-inhibitory-factor (MIF) in malignant tumors have revealed its stimulating influence on cell-cycle progression, angiogenesis and anti-apoptosis...
Evaluation of costs and outcome in cardioembolic stroke or TIAYaroslav Winter
Department of Neurology, Philipps University, Marburg, Germany
J Neurol 256:954-63. 2009..Costs of acute care of cardioembolic stroke/TIA patients may exceed those of non-cardioembolic stroke/TIA by up to 40%...
Cost of illness and its predictors for Parkinson's disease in GermanyAnnika E Spottke
Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany
Pharmacoeconomics 23:817-36. 2005..Total indirect costs amounted to 3180 euro +/-6480 euro. CONCLUSION: According to our study, PD puts a high financial burden on society and underscores the need for further economic and medical research to optimise treatment for PD...
Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-betaKarthikeyan Balakrishnan
Department of Neurology, Philipps University, Marburg, Germany
J Alzheimers Dis 20:135-43. 2010..This information, however, may serve as a guide when choosing the commercial source of IVIG for therapeutic applications in Alzheimer's disease...
Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany-a nationwide population-based study in children and adultsHajo M Hamer
Department of Neurology, Epilepsy Center, University of Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany
J Neurol 259:2376-84. 2012..1/1,000. Family physicians cared for the majority of patients. Prevalence and prescribing patterns changed with age. Costs of AED against epilepsy added up to 1 % of total medication costs in Germany...
Health-related quality of life and its determinants in the urban Russian population with major depressive disorder: a cross-sectional studyYaroslav Winter
Dept of Neurology, Philipps University Marburg, Germany
Int J Psychiatry Med 43:35-49. 2012..The objective of the current study was to evaluate health-related quality of life (HrQoL) and its determinants in outpatients with major depressive disorder in an urban Russian population...
Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settingsJens Peter Reese
Department of Neurology, Philipps University Marburg, Marburg, Germany
J Alzheimers Dis 27:723-36. 2011..Direct medical care costs and long-term care costs related differently to the patient's clinical characteristics. Longitudinal and population-based studies are necessary for thoroughly evaluating the burden of disease...
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial)Richard Dodel
Department of Neurology, Philipps University of Marburg, 35039 Marburg, Germany
Mov Disord 25:97-107. 2010..This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function...
Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based studyYaroslav Winter
Department of Neurology, Philipps University, Marburg, Germany
Mov Disord 25:349-56. 2010..The clinical implication of our study is that it highlights the need for better diagnosis and treatment of depression in early stages of PD...
Reducing sample complexity of polyclonal human autoantibodies by chromatofocusingSascha Hagemann
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Str 8, 35037 Marburg, Germany
J Chromatogr B Analyt Technol Biomed Life Sci 878:2249-54. 2010..g. polyclonal IgG preparations, in order to minimize the amount of different proteins in separated fractions in a reproducible way...
Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophyKarsten Schepelmann
Department of Neurology, Philipps University Marburg, Marburg, Germany
J Neurol 257:15-23. 2010..The socioeconomic burden of NMDs in Germany is considerable. Further studies evaluating both the health-economic and clinical effects of NMD treatment as well as disease management programs and benchmarking activities are necessary...
Frequency and treatment of depressive symptoms in a Parkinson's disease registryAstrid Althaus
Department of Neurology, Philipps University of Marburg, Germany
Parkinsonism Relat Disord 14:626-32. 2008..Large scale randomized controlled trials examining efficacy and safety of antidepressants in PD patients are urgently required...
Long-term outcome after stroke: evaluating health-related quality of life using utility measurementsCaroline Haacke
Department of Neurology, Philipps-University Marburg, Germany
Stroke 37:193-8. 2006..CONCLUSIONS: Our results underscore the importance of nonmotor symptoms on HRQoL in patients with stroke...
Prevalence and incidence of Parkinson's disease in EuropeSonja von Campenhausen
Department of Neurology, Friedrich-Wilhelms-University, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany
Eur Neuropsychopharmacol 15:473-90. 2005..The comparability of existing studies is limited...
Pathogenic and physiological autoantibodies in the central nervous systemMaike Gold
Department of Neurology, Philipps University Marburg, Marburg, Germany
Immunol Rev 248:68-86. 2012..The numerous actions of physiological autoantibodies as well as their regulation and origin are summarized in this review...
Economic burden in a German cohort of patients with multiple sclerosisJens Peter Reese
Department of Neurology, Neurological Therapy Research Group, Philipps University Marburg, Marburg, Germany
Eur Neurol 66:311-21. 2011..To estimate costs of multiple sclerosis (MS) in a German cohort according to severity of the disease and clinical symptoms...
Cost of epilepsy: a systematic reviewAdam Strzelczyk
Department of Neurology, Philipps University, Marburg, Germany
Pharmacoeconomics 26:463-76. 2008..Therefore, there is an urgent need for studies that evaluate direct and indirect costs in a standardized fashion...
Health-related quality of life in patients with a history of myocardial infarction and strokeJan Philipp Bach
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Strasse 8, Marburg, Germany
Cerebrovasc Dis 31:68-76. 2011..There is a lack of the generic data comparing the influence of different diseases on health-related quality of life (HrQoL) in a representative sample of primary care patients...
Copper deficiency associated with severe neurological disorder--a genetic work-up of possible mutations in copper transport proteinsJan Philipp Bach
Department of Neurology, Philipps University Marburg, Rudolf Bultmann Strasse 8, 35039 Marburg, Germany
J Neurol Sci 291:95-7. 2010..Copper deficiency has been described as resulting in severe neurological impairment. However, mechanisms underlying a copper deficiency are presently unknown...
The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicityCarmen Noelker
Department of Neurology, Friedrich-Wilhelms-University, Bonn, Germany
Neurosci Lett 383:39-43. 2005....
Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potentialCarmen Noelker
Department of Neurology, Philipps University Marburg, Germany
Mol Diagn Ther 15:83-102. 2011..This article provides an overview of this field of research and focuses on recent advances in biomarker research in Alzheimer's disease and Parkinson's disease...
Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologistsKarla Eggert
Department of Neurology, Philipps Universitat Marburg, Marburg, Germany
Eur Neurol 61:216-22. 2009..This study evaluates the awareness and the knowledge of the German practice guideline for Parkinson's disease among neurologists...
Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrumentElke Kalbe
Department of Neurology, University Hospital, University of Cologne, Germany
Parkinsonism Relat Disord 14:93-101. 2008..The mood questionnaire also had high sensitivity and specificity. We conclude that the PANDA is an economical, easy-to-use and sensitive tool to detect neuropsychological dysfunctions in PD patients in clinical practice...
Antibody-based therapy in Alzheimer's diseaseRefik Pul
Hannover Medical School, Department of Neurology, Carl Neuberg Str 1, 30625 Hannover, Germany
Expert Opin Biol Ther 11:343-57. 2011..Further results of the clinical trials and new antibody-based approaches will shed light on the importance of Aβ and its removal in AD...
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled studyKarla Eggert
German Competence Network on Parkinson s Disease, Department of Neurology, Philipps University Marburg, Marburg, Germany
Mov Disord 25:896-905. 2010..Adverse events were similar across treatment groups. Perampanel treatment was well tolerated and safe, but failed to achieve statistical significance in primary and secondary endpoints...
Naturally occurring autoantibodies against β-AmyloidJan Philipp Bach
Department of Neurology, Philipps University Marburg, Germany
Adv Exp Med Biol 750:91-9. 2012..The results will show whether the application of NAbs will change the fate of the disease. This chapter summarizes our current knowledge on NAbs against Aβ...
Costs of acute stroke care on regular neurological wards: a comparison with stroke unit settingYaroslav Epifanov
Department of Neurology, Klinikum Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
Health Policy 81:339-49. 2007..Since the resource utilization on regular neurological wards is widely unknown, we determined the costs for acute stroke care on regular neurological wards to compare both treatment settings...
Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathiesJens Reimann
Department of Neurology, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
J Neuropathol Exp Neurol 69:654-62. 2010..These data suggest that MIF is a skeletal muscle cytokine with probable functions beyond inflammatory pathology in the complex regenerative response to muscle fiber damage...
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's diseaseRichard Dodel
Department of Neurology, Philipps University Marburg, Germany
Ann Neurol 52:253-6. 2002..This study provides evidence that intravenous immunoglobulin or purified Abeta antibodies may modify Abeta and Abeta(1-42) levels, suggesting potential utility as a therapy for Alzheimer disease...
Projected numbers of people with movement disorders in the years 2030 and 2050Jan Philipp Bach
Department of Neurology, Philipps University Marburg, Marburg, Germany
Mov Disord 26:2286-90. 2011..Because these disorders pose a major challenge to patients, families, and health care systems, there is a need for reliable data about the future number of affected people...
Cost effectiveness of pharmacotherapies in early Parkinson's diseaseKarla M Eggert
Department of Neurology, Philipps University Marburg, Marburg, Germany
CNS Drugs 22:841-60. 2008..Novel head-to-head comparisons considering the actual treatment guidelines are necessary to identify the most cost-effective alternative in treating de novo Parkinson's disease patients...
CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's diseaseMichael Bacher
Department of Neurology, Philipps University Marburg, 35039 Marburg, Germany
J Exp Med 205:1593-9. 2008..This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD...
Evaluation of the obesity genes FTO and MC4R and the type 2 diabetes mellitus gene TCF7L2 for contribution to stroke risk: The Mannheim-Heidelberg Stroke StudyYaroslav Winter
Department of Neurology, Philipps University Marburg, Marburg, Germany
Obes Facts 4:290-6. 2011..The objective was to investigate the genetic markers related to obesity genes FTO and MC4R and the gene of type 2 diabetes mellitus TCF7L2 for their contribution to risk of stroke and transient ischemic attacks (TIA)...
Theory of mind in Parkinson's disease and related basal ganglia disorders: a systematic reviewMaren Elisabeth Bodden
Department of Neurology, Philipps University, Marburg 35039 Germany
Mov Disord 25:13-27. 2010..The purpose of this review is to provide an overview of research on ToM abilities in basal ganglia disorders, especially Parkinson's Disease and related disorders...
Role of MIF in inflammation and tumorigenesisJan Philipp Bach
Institute of Immunology, Philipps University Marburg, Marburg, Germany
Oncology 75:127-33. 2008..This review provides an overview of the involvement of MIF in both autoimmune disorders and tumorigenesis and summarizes the molecular action of MIF in this context...
Who was the man who discovered the "Lewy bodies"?Antonio M Rodrigues e Silva
Department of Neurology, Philipps University, Marburg, Germany
Mov Disord 25:1765-73. 2010..This article gives a summary of Lewy's life and briefly presents his contribution to German and American neurology...
[Cost and quality aspects in the treatment of Parkinson's disease]Thomas Muller
Neurologische Klinik im St Josef Hospital, Ruhr Universitat Bochum
Z Arztl Fortbild Qualitatssich 100:291-5. 2006..The Parkinsonian patient should benefit from the scientific progress in the treatment of PD. This will improve quality of life and at least decrease the indirect costs of PD on the long term...
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)Oliver Riedel
Institute of Clinical Psychology and Psychotherapy, Technical University of Dresden, Chemnitzer Strasse 46, Dresden, Germany
J Neurol 255:255-64. 2008..Prevalence estimates of these complications are quite variable and are lacking for the outpatient care sector...
Rate of clinical progression in Parkinson's disease. A prospective studyAnette Schrag
Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom
Mov Disord 22:938-45. 2007..However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology...
